Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herbal mix put to the test against psoriasis

NCT ID NCT05295979

Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a Chinese medicine formula called Inflammatory Skin Disease Formula (ISDF) can reduce the severity of plaque psoriasis, a common inflammatory skin condition. Adults with mild to moderate psoriasis will take either ISDF granules or a placebo twice daily for 12 weeks. Researchers will measure changes in skin redness, thickness, and scaling to see if the herbal treatment offers a safer, more affordable alternative to current therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an herbal formula called Inflammatory Skin Disease Formula (ISDF)
What this could lead to
If effective, ISDF could offer a lower-cost, lower-side-effect option for managing psoriasis symptoms.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. Herbal formulas can vary in potency and may still cause side effects or interact with other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

60 people

The number who actually took part.

Started

Mar 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Mild to moderate chronic plaque psoriasis (PASI score 3 to 12). * Willingness to give informed consent. Exclusion Criteria: * Pustular or generalized erythrodermic psoriasis. * Psoriatic arthritis with syndrome of spleen-kidney yang deficiency according to Chinese medicine theory. * Systemic therapy for psoriasis 6 months prior to baseline. * Use topical medications for psoriasis 14 days prior to baseline such as retinoids, corticosteroids, vitamin D analogues, tazarotene and tacrolimus. * Has taken any antibiotics, probiotics and prebiotics 30 days prior to baseline. * UV light therapy 30 days prior to baseline. * Clinically significant laboratory abnormality in blood, liver or renal functions (≥1.5 times the upper limit of reference range). * History of allergy to Chinese herbs. * Unwillingness to comply with study protocol. * Any other condition that in the opinion of the investigators could compromise the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • Hong Kong Institute of Integrative Medicine

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.